Efficacy of a New Spot-On Formulation of Selamectin Plus Sarolaner in the Treatment of Otodectes cynotis in Cats [PDF]
Veterinary Parasitology, 2017 The efficacy of a new spot-on formulation of selamectin/sarolaner was evaluated against induced Otodectes cynotis infestations in cats in two randomized, blinded studies. Fourteen and 16 cats were randomly assigned to treatment groups in Studies 1 and 2, respectively. On Day 0, animals were either treated with placebo or with the spot-on formulation at
Craig Reinemeyer +2 more
exaly +4 more sources
Discovery of Sarolaner: A Novel, Orally Administered, Broad-Spectrum, Isoxazoline Ectoparasiticide for Dogs [PDF]
Veterinary Parasitology, 2016 The novel isoxazoline ectoparasiticide, sarolaner, was identified during a lead optimization program for an orally-active compound with efficacy against fleas and ticks on dogs. The aim of the discovery program was to identify a novel isoxazoline specifically for use in companion animals, beginning with de novo synthesis in the Zoetis research ...
Debra J Woods, Aleah Pullins
exaly +5 more sources
Efficacy and Speed of Kill of a New Spot-On Formulation of Selamectin Plus Sarolaner Against Flea Infestations in Cats [PDF]
Veterinary Parasitology, 2017 The efficacy of a new spot-on formulation of selamectin plus sarolaner against induced flea infestations in cats was confirmed in three placebo-controlled, blinded studies. Purpose-bred adult cats (n=8/group) were blocked by pre-treatment flea counts and randomly allocated to treatment with either a placebo or with the spot-on formulation at the ...
Csilla Becskei +2 more
exaly +4 more sources
The Speed of Kill of a Topical Combination of Selamectin Plus Sarolaner Against Induced Infestations of Ixodes scapularis Ticks on Cats [PDF]
Veterinary Parasitology, 2019 The speed of kill of a novel, topical product containing selamectin in combination with sarolaner (selamectin/sarolaner; Revolution® Plus/Stronghold® Plus) was evaluated against Ixodes scapularis ticks on cats. Sixteen cats were randomly allocated to a treatment group and treated topically on Day 0 with either placebo (vehicle control) or 6 mg/kg ...
William R Everett +2 more
exaly +4 more sources
Efficacy of a New Spot-On Formulation of Selamectin Plus Sarolaner Against Ancylostoma Tubaeforme and Toxocara cati in Cats [PDF]
Veterinary Parasitology, 2017 The efficacy of a new spot-on formulation of selamectin plus sarolaner for cats was evaluated against induced infections with Ancylostoma tubaeforme (hookworm) and Toxocara cati (roundworm). Five laboratory studies were conducted using adult, purpose-bred cats.
Thomas Geurden +2 more
exaly +4 more sources
Efficacy of a New Topical Formulation Containing Selamectin Plus Sarolaner Against Three Common Tick Species Infesting Cats in the United States [PDF]
Veterinary Parasitology, 2019 The efficacy of a single topical application of a combination product containing selamectin and sarolaner (selamectin/sarolaner; Revolution® Plus/Stronghold® Plus) was evaluated in seven laboratory studies against Ixodes scapularis (three studies ...
Sara Chapin +2 more
exaly +2 more sources
Determination of the Effective Dose of a Novel Oral Formulation of Sarolaner (Simparica™) for the Treatment and Month-Long Control of Fleas and Ticks on Dogs [PDF]
Veterinary Parasitology, 2016 Three laboratory studies were conducted to determine the appropriate dose of sarolaner, a novel isoxazoline, for the treatment and month-long control of infestations of fleas and ticks on dogs.
Josephus J Fourie +2 more
exaly +2 more sources
Efficacy of a New Spot-On Formulation of Selamectin Plus Sarolaner Against Four Common Tick Species Infesting Cats in Europe [PDF]
Veterinary Parasitology, 2017 A single application of a new spot-on formulation of selamectin plus sarolaner (Stronghold®Plus, Zoetis) was evaluated for efficacy against the most common tick species infesting cats in Europe.
Csilla Becskei +2 more
exaly +2 more sources
Veterinary Parasitology, 2016 The efficacy of the novel isoxazoline, sarolaner (Simparica™) was investigated in dogs with clinical signs consistent with sarcoptic mange and harbouring natural infestations of Sarcoptes scabiei. One placebo-controlled laboratory study and one multi-centred field study with a commercial comparator containing imidacloprid/moxidectin (Advocate(®) spot ...
Josephus J Fourie +2 more
exaly +3 more sources